Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

Researchers conducted the REDEFINE 1 and REDEFINE 2 clinical trials to assess the effect of CagriSema on weight loss in obesity with or without type 2 diabetes.

The percentage of participants who achieved at least 25% weight loss was 34.7% in the CagriSema group, 14.8% in the semaglutide group and 6.5% in the cagrilintide group, while the percentage that ...

A NEW Phase 3 trial has shown that a combination therapy of cagrilintide and semaglutide (CagriSema) can lead to substantial ...

CagriSema patients lost more weight than those taking either component alone: 20.4% for the combination vs 11.5% with cagrilintide, 14.9% with semaglutide, and 3% with placebo.

By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Shares in Novo Nordisk fell as much as 3.5% on Monday after detailed trial data on its experimental obesity drug CagriSema fuelled ...

CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and semaglutide 2.4 mg. CagriSema is not approved in the US for weight loss.

CagriSema led to a 20.4% weight loss at 68 weeks vs. 3.0% with placebo in adults without diabetes. 50.7% of CagriSema users with obesity reached a BMI under 30, compared to 10.2% in the placebo ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in late ...

Novo Nordisk, the manufacturer of both, recently shared that CagriSema may lead to 10 percent more weight loss than Wegovy. Here’s what we know so far about this promising new option for.

When adhering to treatment, weight loss of ≥5%, ≥20%, ≥25%, and ≥30% was observed in 97.6%, 60.2%, 40.4% and 23.1% of patients respectively at 68 weeks 1* The REDEFINE clinical program is ...